In June 2021 our group moved from UAB Campus at Bellaterra to VHIR Institute.
During 2021, we futher developed the two main research projects carried out in our laboratory: a) deciphering the role of MAP kinase ERK5 in cancer cells; and b) suporting clinical phase 2 study of the new anticancer drug ABTL0812 in pancreatic cancer patients (in collaboration with Ability Phamaceuticals S.L.). Our work was published in five D1 and Q1 international journals.
In June 2021, Nora Diguez succesfully defended her PhD Thesis. We also trained two Master Students that successfully defended  their Mastter Thesis (TFMs) in September 2021. One more VHIR Master student joined the goup in October 2021.
In September 2021, Dr. Gohkan Gorgisen (Associated Professor at Van Yuzuncu Yil University, Turkey) joined the group, founded by the turkish government

Group Leader
Jose Miguel Lizcano De Vega

Gokhan Görinsen, Nora Diéguez Martínez

PhD Students
Sergio Espinosa Gil, Idoia Bolinaga Ayala

Lab Technicians
Elisabet Megías Roda








Muñoz-Guardiola P, Casas J, Megías-Roda E, Solé S, Perez-Montoyo H, Yeste-Velasco M, Erazo T, Diéguez-Martínez N, Espinosa-Gil S, Muñoz-Pinedo C, Yoldi G, Abad JL, Segura MF, Moran T, Romeo M, Bosch-Barrera J, Oaknin A, Alfón J, Domènech C, Fabriàs G, Velasco G, Lizcano JM
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.
Autophagy. 2021 Jun;17(6):1349-1366.
DOI: doi: 10.1080/15548627.2020.1761651
IF: 16.02

Gámez-García A, Bolinaga-Ayala I, Yoldi G, Espinosa-Gil S, Diéguez-Martínez N, Megías-Roda E, Muñoz-Guardiola P, Lizcano JM
ERK5 Inhibition Induces Autophagy-Mediated Cancer Cell Death by Activating ER Stress.
Frontiers in Cell and Developmental Biology. 2021 Nov 4;9:742049.
DOI: doi: 10.3389/fcell.2021.742049
IF: 6.68

Vidal L, Victoria I, Gaba L, Martín MG, Brunet M, Colom H, Cortal M, Gómez-Ferrería M, Yeste-Velasco M, Perez A, Rodon J, Sohal DPS, Lizcano JM, Domènech C, Alfón J, Gascón P.
A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.
European Journal of Cancer. 2021 Mar;146:87-94
DOI: doi: 10.1016/j.ejca.2020.12.019
IF: 9.16

Leiva-Rodríguez T, Romeo-Guitart D, Herrando-Grabulosa M, Muñoz-Guardiola P, Polo M, Bañuls C, Petegnief V, Bosch A, Lizcano JM, Apostolova N, Forés J, Casas C.
GRP78 Overexpression Triggers PINK1-IP3R-Mediated Neuroprotective Mitophagy.
Biomedicines. 2021 Aug 18;9(8):1039. doi: 10.3390/biomedicines9081039
IF: 6.08

Nuevas terapias anticáncer basadas en la modulación de la MAP kinasa ERK5
Principal Investigator: Jose Miguel Lizcano de Vega
Agency: Ministerio de Ciencia e Innovación
Funding: 13,100€
Period: 2020-2023

Nuevas estrategias para incrementar efectividad de los tratamientos anticáncer con ABTL0812
Principal Investigator: Jose Miguel Lizcano de Vega
Agency: Ministerio de Economía y Competitividad (MMINECO)
Funding: 346,877€
Period: 2018-2021